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In order to prepare a preliminary analysis of the Brazilian National Innovation System in Biotechnology (NISB), we 
conducted several interviews and used e-mail questionnaires with different kinds of actors in the system, i.e. university 
teachers, financing agents, businessmen, etc. The study suggests that Brazil has a few important strong points, like the 
scientific tradition in biotechnology, the financing to basic research and the strength of the agricultural sector in the last 
decade. But there is still a long way to go; sector regulation, the start up companies financing and the cultural aspect of 
business aversion by researchers seem to be the main obstacles for the country to become a significant player in this sector 
 





Modern biotechnology has been suggested as the new 
economic wave following the Internet wave. Several 
countries have tried to establish a national system of 
innovation in biotechnology that would allow the 
optimization of scientific and economic resources and 
would generate products based on a national biotechnology. 
Bartholomew (1997) has suggested a model for analyzing 
systems of innovation in biotechnology in various 
countries, listing their common factors. Based on that 
model, we have prepared a preliminary analysis of the 
Brazilian system of biotechnology innovation, in order to 




Through interviews and questionnaires we establish a 
general picture of the situation in the country according to 
the several players who are involved in the system –  
 
graduate students, professors, promotional and regulatory 
agents, business people and policymakers. 
Our results suggest that Brazil still has a long way to go in 
organizing its innovation system in biotechnology. Sector 
regulations, the financing of start-up companies and the 
aversion of researchers to businesses appear as the main 
obstacles to establishing the country as a significant world 
player in this sector. The strong points include the country’s 
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2. National Innovation Systems 
 
The National Innovation System (NIS) concept is based on 
the principle that the relationships between different players 
involved in innovation are determinant for improving the 
performance and utilization of technology. Innovation and 
technical progress are the result of a complex set of 
relationships among those who produce, distribute and 
apply various types of knowledge. A country’s innovative 
performance largely depends on how these players relate 
with one another. The players are private companies, 
universities and public research institutions and the people 
within them. Relationships can result from cooperative 
research, personal exchanges, co-patenting, the purchasing 
of equipment, and a variety of other possibilities. On the 
other hand, there is no consensual definition concerning a 
national innovation system (OECD, 1996; OECD, 1997). 
Various definitions have been offered by different authors 
(e.g. Freeman, 1987; Lundvall, 1992; Nelson, 1993; Patel 
and Pavitt, 1994; Metcalfe, 1995). Thus, many analysts 
have created methods for analyzing NISs, looking for 
national patterns that may be adapted by other nations in 
order to improve the local NIS. 
In the present study we are concerned with national 
innovation systems in Biotechnology. Modern 
Biotechnology has been receiving great emphasis 
nowadays. The economic possibilities, the ethical issues 
involved in manipulating live organisms, the issue as to 
whether or not transgenic foods are harmful, and the 
possible treatment of diseases that had formerly been 
considered incurable are making headlines all over the 
world. 
However, contrary to other economic sectors, 
Biotechnology is not an activity per se. It deals with a set of 
techniques, knowledge and technologies that may be 
productively used in other sectors. As a rule, this 
knowledge and these techniques are developed in academia 
and in other research institutions, while their utilization 
occurs in industry. As such, the diffusion of new 
technologies has become the key factor for a country’s 
success in this field, making it necessary the use of 
somewhat different tools for the analysis of this specific 
innovation system. It is no wonder that the majority of first 
world countries have already set up a specific innovation 
system for Biotechnology1.  
The objective of this study is to present an analysis of the 
current state of biotechnological development in Brazil, 
using the model developed by Bartholomew in 1997 for 
national systems of innovation in Biotechnology. Through 
interviews and e-mail questionnaires submitted to 
individuals working in the area, a preliminary picture was 
                                                 
1See http://www.sussex.ac.uk/spru/biotechnology/ebis/ for 
a view of the systems established by European countries. 
  
obtained, concerning the country’s strong and weak points 




Biotechnology is one of humankind’s oldest areas of 
knowledge. Contrary to what is normally suggested, 
techniques for manipulating living beings have existed for 
many centuries. Bread, beer and wine, perhaps the oldest 
products ever manufactured, are nothing more than 
products originating from the fermentation of 
microorganisms in a favorable medium, in this case, wheat 
or grapes. However, modern biotechnology, capable of 
manipulating an organism and its own genetic code, of 
modifying tissues and cells in vivo, has captured the 
attention of the media, economists, policymakers, 
researchers and scholars. Modern biotechnology was 
developed over the course of the 20th century, with 
explosive growth towards its last quarter and promising to 
create a new economic boom. One could present a long list 
of areas in which biotechnology is used today but it would 
certainly not be exhaustive. From the point of view of 
economic potential, the areas of greater impact nowadays 
and in the near future, according to several authors, are 
proteomics (the identification of spatial structures in 
proteins), pharmaceuticals, bioengineering, biomaterials 
and genetically modified foods. It is this modern 
biotechnology that is the object of the present study. 
  
4. Bartholomew’s Model for Analyzing an NIS of 
Biotechnology  
 
The idea of a national innovation system differentiated for 
Biotechnology has already been discussed by various 
authors (e.g. Balazs and Twardowski, 2000; Senker et al., 
1999; Chen and McDermott, 1998). Biotechnology 
generates ways of attaining new products, not products per 
se. Such ways may then be utilized in other sectors (e.g. the 
pharmaceutical, food and agricultural industries). As such, 
the system has become much more complex and the 
diffusion of new technologies has become critical for its 
success (Senker et al., 1999). 
Bartholomew (1997) proposed a model for analyzing 
national systems, making it possible to find strong points 
and obstacles in each country by analyzing eleven factors 
with historical, social, economic and political causes that 
are specific to each country, and which will provide a 
greater or lesser ease in the development of Biotechnology. 
This model was well received by the academic community 
(an earlier version won the Haynes Prize of 1996, 
sponsored by the AIB Foundation and the Eldridge Haynes 
Memorial Trust), and we believe it allows for the inclusion 
of most of the critical factors suggested in the literature on 
NSI in Biotechnology. The model (see figure 4.1) is based 
on 11 factors influencing the innovation system. The factors 
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Figure 4.1 – Model for analyzing an NIS 
 
 
5. Analysis of the Brazilian NSI in B
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from the National Council for Scientific and Technological 
Development and the Ministry of Science and Technology. 
We used open interviews, trying to cover all the points 
discussed on in the model. The interviewees and 
respondents were guaranteed anonymity and only their area 
of involvement is mentioned here. The number of 
interviewees and respondents to questionnaires can be seen 
in table 5.1. 
 
Table 5.1 – Interviewees and Questionnaires respondents 
 Interviews Questionnaires 
Graduate Students  2 5 
University Professors  2 8 
Research Institute Researchers - 3 
Venture Capital Professionals 2 1 
Biotech Professionals in Start-up Companies 1 2 
Biotech Professionals in Large Companies - 3 
Government Officials 1 12 




Respondents were asked to give their opinions about the 
eleven factors of the Bartholomew model on a Likert scale 
varying from 0 (non-existent) to 5 (excellent). Results are 
presented in Table 5.2 and will be discussed below. The 
discussion will also take into account the opinions 
expressed in the interviews. 
 
Table 5.2 – Perceptions of respondents about the situation in Brazil in the area of Biotechnology (0 = nonexistent; 1 = bad; 2 
= weak; 3 = average; 4 = good; 5 = excellent). 
 
Factors Average 
Relationship of Research Institutes with Foreign Institutions 3.1 
National Tradition of Scientific Education 3.2 
National Financing for Basic Research  2.7 
Commercial Orientation of Research Institutions  1.4 
Mobility of Work Force  1.8 
Venture Capital Market 2.0 
Government Involvement in Diffusion of Technologies 2.4 
Accumulation of Technology in Correlated Sectors 3.0 
Collaboration between Industry and Research Institutes 2.1 
Cooperation among Companies in R&D 2.0 
Strategic Utilization of Foreign Technology 2.4 
 
  
Relationship of Research Institutes with Foreign 
Institutions 
 
According to the interviewees and respondents, our 
research institutions and universities have a good 
relationship with foreign institutions. The average score 
obtained on our questionnaires for this factor was 3.1, the 
second highest among the 11 factors assessed. The strong 
point of this relationship is in research, where the flow of 
scientists and students abroad is constant and embodies all 
the areas related to Biotechnology. There is a large 
contingent of students working on their doctoral who spend 
from 6 months to a year doing research in foreign 
universities, as well as a large number of post-doctorates, 
especially in the U.S. and Europe (notably France and 
England).  
 
National Tradition of Scientific Education 
 
According to respondents (and interviewees) this is the 
country’s strong point in the Biotechnology area. This 
factor achieved the highest average score of all 11 factors, 
3.2. 
Brazil has always produced a large number of professionals 
in the area of Biotechnology. According to the 
interviewees, the problem with this factor is not supply, but 
demand; there is a lack of risk capital, commercial 
orientation by companies and even public financing (as we 
shall soon see); as a consequence, there is a surplus of 
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qualified professionals, who are often lost to other sectors 
of the economy due to a lack of places at universities, 
research institutions and companies. 
 
National Financing for Basic Research 
 
This factor, in spite of having received a good average 
score (2.7) presented a large variability of responses, not 
only among the questionnaire respondents but also among 
the interviewees. While some of them consider it to be good 
and, in some cases, “exceptional,” a good part of the 
respondents find government involvement in supporting 
research quite weak or “barely tolerable.” The main 
complaint of the interviewees was the government’s lack of 
constant financial support. According to the interviewees, 
funds are always late in coming and quite often projects 
that are already underway fail to receive the agreed budget. 
  
Commercial Orientation of Research Institutions 
 
The lack of commercial orientation seems to be as main 
deficiency in the national system of innovation in 
Biotechnology. Both in the interviews and in several 
spontaneous opinions presented in the questionnaires, it 
became clear that the cultural aspect is the first barrier to 
biotechnology in Brazil. For them, researchers seem to 
believe that their only job is to practice science, and that the 
idea of trying to earn money as a product of their research 
is not proper. The scientific community looks down on 
researchers who turn to a career in industry or who become 
entrepreneurs and create their own business. It was further 
cited that Brazilians generally have an aversion to 
entrepreneurs, associating their image to those who take 
advantage of others to get money, as opposed to 
researchers, who have an image of pure dedication, 




This factor received the second lowest mean score (1.8). 
However, the majority of the interviewees, as well as some 
of the respondents, stated that they were not adequately 
familiar with the subject. Several suggested that Brazilian 
mobility was rather low as compared to European or North 
American mobility, a suggestion which may well be right 
(for a discussion of mobility in Brazil, see Pastore & Valle 
Silva, 2000; Scalon, 1999).  
Although the cultural aspect may be a major factor for low 
mobility, some interviewees also suggested that the (lack 
of) demand from industry (e.g. pharmaceuticals) could also 
be blamed; many companies prefer to develop new 
products at headquarters and/or research centers abroad. 
  
Venture Capital Market 
 
New Biotechnology companies are born in universities and 
research centers when researchers see the possibility of 
creating an innovative and lucrative business. In the 
overwhelming majority of cases, researchers’ own funds 
are insufficient for creating a new company with 
equipment, personnel and funding for research continuity. 
Thus, there is a strong dependence on capital investment. 
On top of that, unlike sectors such as information 
technology, where a group of software developers can 
develop an excellent new product “in their garage” and put 
it on the market to generate revenue, in Biotechnology the 
initial investment required is very large (Robbins-Roth, 
2000). 
But venture capital is still embryonic in the country 
(average score was 2.0) and faces a serious obstacle in the 
particular area of Biotechnology: legislation. If the “rules of 
the game” are not well defined, it is not possible for the 
investor to assume further risks, with possible changes in 
the Biodiversity law, the biotechnology product patent law, 
and regulations concerning the functioning of companies 
based on biotechnology. Researchers and students showed 
concern about the fact that the (small) supply of risk capital 
has become restricted to the Rio – São Paulo hub. 
  
Government Involvement in Diffusion of Technologies 
 
Diffusion is the process by which an innovation is 
communicated over time through determined channels by 
members of a specific social system (Rogers, 1995). Since 
Biotechnology is strongly dependent on basic research, its 
success in any country is strongly connected to government 
policies concerning science and its diffusion. This is not a 
very simple matter because biotechnologies seem to diffuse 
differently in different sectors of the economy.  This was 
confirmed by respondents to the questionnaire who 
indicated differences in diffusion between the agro-business 
and the pharmaceutical sectors (good diffusion in agro-
business and not good in pharmaceuticals). The average 
score was 2,4 
 
Accumulation of Technology in Related Sectors 
 
Similar to diffusion one finds a clear distinction between 
different sectors of the economy (here, the agricultural 
sector and the health sector) with respect to accumulation. 
Both the interviews and the comments provided in the 
questionnaires indicate that although in the average this 
factor is well rated (3.0), it is clear that agriculture enjoys 
much more accumulated knowledge than health. In several 
questionnaires,  
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Company Collaboration with Research Institutions 
 
Industrial innovation depends on the integration of applied 
research and development. However, such integration does 
not occur automatically and the efficiency with which a 
company transfer applied research to final products and 
processes is a key factor for success. Biotechnology is still 
strongly dependent on basic research (generated, as a rule, 
at universities).  
This factor did not receive a good evaluation from both 
interviewees and respondents. With a 2.1 average, the 
common feeling is that industry and universities do not 
communicate with each other, creating a barrier to 
Biotechnological development. It is important to mention 
that there were some very positive comments about the 
interaction between some non-academic research 
institutions and local industry (EMBRAPA and the rural 
producers and Fiocruz and pharmaceutical companies in 
drug development). 
 
Cooperation among Research and Development Companies 
 
In modern industries, competition is now seen as a race for 
learning. Collaboration among organizations (companies, 
universities and others) has grown over the last few years, 
especially in sectors such as Biotechnology. But this does 
not seem to hold in Brazil. The interviews suggested that 
there was very little cooperation and the explanation was 
that the biotechnology industry is still quite small and new. 
Respondents to the questionnaires also indicated that this 
may be so; 15% of the respondents did not answer this 
question and some 20% mentioned that their answer 
applied to the general collaborative situation among 
companies in the country, but not to Biotechnology 
companies.  
 
Strategic Utilization of Foreign Technology 
 
Similarly to the previous factor, size and age of the industry 
seem to diminish the importance of the strategic use of 
foreign technology. The majority of the interviewees 
showed that they did not know of practical cases where 
technologies in the productive sector were strategically 
utilized. In research, however, all pointed out the constant 
search by researchers for new methodologies, and to the 
fact that each year many doctoral students go abroad to be 
trained in new methods. Quite naturally, this transfer of 
knowledge applies only to the field of research. It will be 
used by the productive sector only in cases of company 
start-ups initiated by the student him/herself or by his/her 
professor. As one interviewee pointed out there is some use 
of foreign technology by the Fiocruz Foundation for the 
production and development of new vaccines. Although of 
great importance for the country, the volume of the 
operation in industrial terms is still small. 
 
5.3 Strong and Weak Points of Biotechnology in Brazil 
 
As mentioned before, the main objective of this paper is to 
discuss the strengths and weaknesses of the Brazilian NSI 
in Biotechnology. In other words, what are the strong and 
weak points for the development of a national system of 
innovation in biotechnology in Brazil? 
According to our results, we are still quite far from those 
countries that are on the cutting edge of biotechnological 
development. Not one single factor was considered 
“excellent” (five) or “good” (four). The best factor 
(National Tradition of Scientific Education) was rated just a 
little above “average” (3.2). 
Nevertheless, there are positive aspects in the current state 
of the situation. The scientific tradition is a favorable point 
in the development of new technologies and processes. 
Financing of basic research, in spite of being less than what 
is desired by the scientific community, is another positive 
factor. We suggest that a good supply of human resources 
coupled with a reasonably good financing of research, 
represent a very good start for the creation of a strong 
internal knowledge, which is the support for the entire 
innovation system. 
The current state of agriculture in the country was also 
emphasized during several interviews and (written) 
comments in the questionnaires. The system formed by the 
universities, EMBRAPA, and the diffusion to the producer 
was highly approved by the respondents.  
As for the main difficulties one can point to the lack of 
consistency in financing for research, the cultural reaction 
to entrepreneurial activities, the difficulty of finding 
financing for the final steps of product development and 
company start-ups, the legislation now in force, the lack of 
a specific policy for diffusing technologies in the area of 
health, the non-commercial orientation of research 
institutions, and the lack of labor mobility between the 
university and the productive sector. Two of such 
difficulties were strongly emphasized by respondents and 
we will comment on them next.   
 
 
6. Two major Difficulties in the NIS in 
Biotechnology in Brazil: Venture Capital and 
Legislation 
 
As mentioned previously, a large number of problems were 
identified in this study. Many of them were circumstantial, 
such as the discontinuity in public financing for research, 
while some affect only certain activities, such as the lack of 
a specific policy for diffusing technologies in the area of 
health. 
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However, some of the problems identified seem to be very 
relevant and have a great potential for making the 
development of the system very difficult. Two of such 
problems were (i) the issue of financing a start-up 
company, which in the rest of the world is traditionally 
done in the form of venture capital (Robbins-Roth, 2000; 
Senker, 1996); and (ii) the country’s as yet undefined 
legislation. The frequency and emphasis with which they 
were mentioned suggest that they are the main obstacles to 
biotechnology in Brazil. These two problems deserve our 
special attention and are presented next in greater detail. 
 
6.1 Venture Capital 
 
6.1.1 Technological Based Companies and the Need for 
Venture Capital 
 
The traditional financing mechanisms available through 
financial institutions are not the most appropriate for base 
technology companies. This is due to the risky nature of the 
activities of such companies, which involve intense 
investment in Research and Development, and the profile of 
their founders, who do not usually possess enough real 
assets to secure a loan. 
Risk capital, besides not requiring security, implies that 
returns for investors depend on the growth and profitability 
of the company in question, which is contrary to traditional 
credit where the creditor has legal rights in terms of interest 
and amortization, regardless of the success or failure of the 
business. Furthermore, such a financing mechanism differs 
from other traditional sources because it provides long-term 
capital and offers managerial and administrative support 
(British Venture Capital Association, 2000). 
 
 
6.1.2 The Venture Capital Market in Brazil 
 
Venture capital in Brazil stated in the 1970s, primarily 
through two public institutions, BNDES, the National Bank 
for Economic and Social Development and FINEP2  
(Gorgulho, 1997). 
Support from BNDES, through its subsidiary, BNDES-
Participações (BNDESPAR), is one of the pioneering 
experiences in Brazil in terms of financing the process of 
innovation through risk capital. Especially in the cases of 
small and medium-sized companies, support is relatively 
recent (beginning in 1988) through the Capitalization 
                                                 
2 Financiadora de Estudos e Projetos — FINEP (Research 
and Projects Financing), also known as the Brazilian 
Innovation Agency, is a publicly owned company 
subordinated to the Ministry of Science and Technology — 
MCT. 
 
Program for Technology Based Companies (CONTEC) 
(Gorgulho, 1997). Nowadays the main program for 
diffusing Venture Capital in the country is FINEP’s Project 
INOVAR, which has already put together nearly one 
hundred companies and their risk investors. 
 
6.1.3 Biotechnology Companies and Venture Capital 
 
For a Biotechnology company to grow, several rounds of 
ever-increasing investments are generally necessary. It is 
usual for such investments go over the $30 million mark 
(Robbins-Roth, 2000). This need for large quantities of 
resources may be explained by the fact that the great 
majority of biotechnological companies in the U.S. are 
geared toward developing new medicines, which implies 
the need for FDA approval. This is a long process and 
consumes a large amount of resources. 
Therefore, it becomes evident that the entrepreneur will 
hardly possess enough personal resources to set up his 
company. Since the Brazilian pharmaceutical industry is 
quite limited (in terms of investment funds) and developing 
new drugs is usually done abroad, Brazilian companies do 
not have the financial ability to subsidize the needed 
expenses. 
Without the help of State Financing Organizations (which 
are ill equipped to deal with this kind of investment) and 
considering that the term of investment and the volume of 
resources are outside the usual limits of bank financing, the 
alternative for potential entrepreneurs is the traditional 
financial credit 
It has become clear that the country’s Biotechnology 
development depends on the creation of (unsecured) long-
term financing mechanisms on the part of the government, 
or else on the growth and consolidation of the Venture 
Capital industry. 
 
6.2 Brazilian Legislation in Biotechnology 
 
According to the interviewees and respondents to the 
questionnaires, the second major difficulty faced by 
entrepreneurs and risk capitalists is the Brazilian 
Legislation in Biotechnology. All agree that the present 
legislation is rather vague with reference to the 
development of biotechnological products (or leave room 
for interpretation), making it very risky for entrepreneurs 
and risk capitalists. 
The main difficulties are: 
 Patent law, which presumably protects the rights 
of the inventor of a new product or process, and 
which is fundamental for the profitability of any 
Biotechnological undertaking (once a new drug or 
cell is created, it can be easily replicated); 
 Biodiversity law, which starting with the Rio-92 
conference, has determined that the information on 
the genetic structure of the biological resources 
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(flora, fauna, microorganisms) located in a 
particular country is the property of that country. 
This law and its internal regulations have direct 
implications on the possibilities of exploiting 
Biotechnology in Brazil; and 
 Biosecurity law, which imposes limits on the 
manipulation of living organisms, as well as on the 
way they are manipulated and the competence of 
whoever manipulates them. 
 
Even in the most developed countries the legislation 
applying to products derived from biotechnological 
modifications is still a difficult subject. While the European 
countries have placed regulations on GMOs (genetically 
modified organisms) to deal with the process, in Japan and 
the U.S. there seems to be a preoccupation with regulations 
that deal with the product. The labeling of transgenic 
products is also still quite controversial, and it has resulted 
in a split between the U.S. and Europe (Chen and 
McDermott, 1998). 
 
With respect to regulatory policies, it seems that all 
countries are concerned with the potential risks of 
Biotechnology, and the U.S. has initiated a process of 
regulating the sector with this variable in mind. Some 
countries have created specific legislation for 
Biotechnology, while others are regulating the sector based 
on the way other existing sectors are regulated (simply 
adapting already existing laws). The strictness of the laws 
appears to be directly linked to the public’s perception of 
the biotechnology issue, with Germany displaying the 
highest degree of strictness. With respect to intellectual 
property, sharp differences are observed with direct 
implications on the industry’s structure, possibilities and 
growth. The most controversial issue concerns the 
patentability of life forms. Microorganisms are patentable 
in all the countries studied, but transgenic animals are only 
patentable in the U.S. and Japan. Another issue that 
deserves special attention is the use of its genetic 
information. There is a need for strict and specific 
legislation and strict control over the exploitation and use of 
such biodiversity, or countries like Brazil may lose all its 
genetic wealth to countries that are further advanced in the 
biotechnological race. 
Interviews with specialists in the area made it clear that 
such laws are very much open to interpretation. Without 
having to dwell further on the legal considerations, it seems 
clear that there are two main lines of thought: those who 
defend the patenting of basically all new molecules and 
organisms created in the laboratory, and those who think 







The problems related to legislation and the financing of 
start-ups and small and medium-sized companies are no 
doubt quite difficult, and we suggest that such problems 
could be solved (in the long run) given the political will of 
legislators and Government. The cultural problem is also 
very difficult, with its solution only envisaged in the very 
long term through a change in the mentality of researchers 
and, in some way, of the population in general. Such a 
change can in fact take more than one generation to happen 
and never by a single leap. 
Nevertheless, several measures such as the federal 
government proposed Innovation Law and the concern of 
some universities (patent protection policies) to secure their 
rights over research developed in their laboratories may 
well help to overcome the obstacle of commercial 
orientation. 
One issue raised during some of the interviews was the fact 
that the scientific and technological structure of the country 
is based on the Brazilian scientific community. Most of the 
financing is decided by members of the scientific 
community and there is some fear that funds will be biased 
towards basic research. Some steps taken by the Federal 
Government (Innovation Law and the creation of Sector 
Funds) suggest however, that this picture can be changing. 
We suggest that an alternative to the financing of “science 
through science” would be to develop work plans with 
well-defined economic objectives and that have some 
impact on the country’s imports and/or exports. A 
successful example of planning for this type of action has 
occurred in India with the growing of cardamom (Mehra, 
2000). 
Therefore, our conclusion is that policy makers, in order to 
develop Biotechnology in the country must: 
 Work on the legislation for the sector in order to 
attract new investments; 
 Develop new financing mechanisms that are 
adequate for industry know-how and with 
sufficiently long maturities; 
 Create programs focused on the real problems of 
the country, seeking to develop in-house solutions 
with Brazilian competencies and companies, and 
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